May 11, 2015 | The medical device company EndoChoice has filed with the SEC to raised $115 million in a NYSE IPO. The company is expected to be valued at around $500 million. EndoChoice is a US-based company that develops treatments for digestive tract disorders. The company has a development center in Israel with about 70 employees. EndoChoice was founded in 2008 by Mark Gilreath and Will Parks.
Related posts
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023
ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments